AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer
The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based ...
Eventful Monday For AstraZeneca - What's Going On?
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the CALYPSO Phase 3 trial designed to evaluate the efficacy and ...
PharmiWeb4d
Eneboparatide met primary endpoint of normalising…
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...
PipelineReview.com4d
Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial
LONDON, UK I March 17, 2025 I High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary ...